DE2443492C2 - - Google Patents
Info
- Publication number
- DE2443492C2 DE2443492C2 DE2443492A DE2443492A DE2443492C2 DE 2443492 C2 DE2443492 C2 DE 2443492C2 DE 2443492 A DE2443492 A DE 2443492A DE 2443492 A DE2443492 A DE 2443492A DE 2443492 C2 DE2443492 C2 DE 2443492C2
- Authority
- DE
- Germany
- Prior art keywords
- mercaptopropionylglycine
- alkali salts
- muccus
- sodium salt
- determined
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- YTGJWQPHMWSCST-UHFFFAOYSA-N Tiopronin Chemical compound CC(S)C(=O)NCC(O)=O YTGJWQPHMWSCST-UHFFFAOYSA-N 0.000 claims description 29
- 108010058907 Tiopronin Proteins 0.000 claims description 29
- 150000001447 alkali salts Chemical class 0.000 claims description 13
- 159000000000 sodium salts Chemical class 0.000 claims description 9
- 208000023504 respiratory system disease Diseases 0.000 claims description 4
- 239000000654 additive Substances 0.000 claims description 2
- 239000000969 carrier Substances 0.000 claims description 2
- 210000003097 mucus Anatomy 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 4
- 210000004400 mucous membrane Anatomy 0.000 description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
- 230000000694 effects Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- QKHQITUHYKZKJI-UHFFFAOYSA-N 2-benzylsulfanylpropanoic acid Chemical compound OC(=O)C(C)SCC1=CC=CC=C1 QKHQITUHYKZKJI-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- GBFLZEXEOZUWRN-VKHMYHEASA-N S-carboxymethyl-L-cysteine Chemical compound OC(=O)[C@@H](N)CSCC(O)=O GBFLZEXEOZUWRN-VKHMYHEASA-N 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- SXZQVFPZKHBROS-UHFFFAOYSA-N 2-(2-benzylsulfanylpropanoylamino)acetic acid Chemical compound C(C1=CC=CC=C1)SC(C(=O)NCC(=O)O)C SXZQVFPZKHBROS-UHFFFAOYSA-N 0.000 description 1
- IYLZTRHFBLRIJC-UHFFFAOYSA-N 2-benzylsulfanylpropanoyl chloride Chemical compound ClC(=O)C(C)SCC1=CC=CC=C1 IYLZTRHFBLRIJC-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 206010012435 Dermatitis and eczema Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- 241000978776 Senegalia senegal Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 229960004308 acetylcysteine Drugs 0.000 description 1
- 239000000729 antidote Substances 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- -1 injectables Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229910003002 lithium salt Inorganic materials 0.000 description 1
- 159000000002 lithium salts Chemical class 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000000510 mucolytic effect Effects 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 239000002687 nonaqueous vehicle Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 201000004193 respiratory failure Diseases 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 201000009890 sinusitis Diseases 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US00397865A US3857951A (en) | 1973-09-14 | 1973-09-14 | Use of 2-mercaptopropionylglycine and its alkali metal salts in treating respiratory diseases |
Publications (2)
Publication Number | Publication Date |
---|---|
DE2443492A1 DE2443492A1 (de) | 1975-03-27 |
DE2443492C2 true DE2443492C2 (en:Method) | 1987-06-11 |
Family
ID=23572987
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE2443492A Granted DE2443492A1 (de) | 1973-09-14 | 1974-09-11 | Mittel zur behandlung der atmungswege |
Country Status (6)
Country | Link |
---|---|
US (1) | US3857951A (en:Method) |
BE (1) | BE819823A (en:Method) |
CA (1) | CA1026233A (en:Method) |
DE (1) | DE2443492A1 (en:Method) |
GB (1) | GB1482651A (en:Method) |
ZA (1) | ZA745219B (en:Method) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4140786A (en) * | 1976-05-10 | 1979-02-20 | E. R. Squibb & Sons, Inc. | Method for alleviating angiotensin related hypertension |
US4053651A (en) * | 1976-05-10 | 1977-10-11 | E. R. Squibb & Sons, Inc. | Compounds and method for alleviating angiotensin related hypertension |
US4199512A (en) * | 1976-05-10 | 1980-04-22 | E. R. Squibb & Sons, Inc. | Compounds for alleviating hypertension |
US4113715A (en) * | 1977-01-17 | 1978-09-12 | E. R. Squibb & Sons, Inc. | Amino acid derivatives |
US4093739A (en) * | 1977-06-15 | 1978-06-06 | Mead Johnson & Company | Mercaptoacylamidobenzoyl glycine and mucolytic process |
IT1098328B (it) * | 1978-06-16 | 1985-09-07 | Gargani Pietro | Sale sodico della mercapropropionilglicina,processo per la sua preparazione e suoi impieghi terapeutici |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR226M (fr) * | 1960-08-19 | 1961-02-27 | Rech S Et Propagande Scient | Médicament soufré, utilisable en particulier en oto-rhino-laryngologie et en pneumologie. |
FR1491204A (fr) * | 1962-08-10 | 1967-08-11 | Santen Pharmaceutical Co Ltd | Procédés pour la préparation des alpha-et beta mercaptopropionylglycocolle et de leurs dérivés |
GB1114313A (en) * | 1964-11-19 | 1968-05-22 | Wyeth John & Brother Ltd | Pharmaceutical compositions |
-
1973
- 1973-09-14 US US00397865A patent/US3857951A/en not_active Expired - Lifetime
-
1974
- 1974-08-14 ZA ZA00745219A patent/ZA745219B/xx unknown
- 1974-09-11 DE DE2443492A patent/DE2443492A1/de active Granted
- 1974-09-12 BE BE148442A patent/BE819823A/xx not_active IP Right Cessation
- 1974-09-13 CA CA209,355A patent/CA1026233A/en not_active Expired
- 1974-09-16 GB GB40312/74A patent/GB1482651A/en not_active Expired
Also Published As
Publication number | Publication date |
---|---|
GB1482651A (en) | 1977-08-10 |
ZA745219B (en) | 1975-09-24 |
DE2443492A1 (de) | 1975-03-27 |
AU7139474A (en) | 1976-01-22 |
BE819823A (fr) | 1975-03-12 |
CA1026233A (en) | 1978-02-14 |
US3857951A (en) | 1974-12-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE68916385T2 (de) | Stabilisierte Formulierungen mit hydrohoben Proteinen. | |
DE3587928T2 (de) | N-Acetylneuraminsäure und deren Salze enthaltende Expektorantien. | |
DE2501787A1 (de) | Verfahren zur herstellung von wismuthaltigen arzneipraeparaten | |
DE69320968T2 (de) | Neue bioaktive zusammensetzungen, ihre herstellung und verwendung | |
DE2443492C2 (en:Method) | ||
DE3319282C2 (en:Method) | ||
DE3000743C2 (de) | Arzneipräparat auf der Basis eines Salzes der Acetylsalicylsäure und einer basischen Aminosäure | |
DE2433209A1 (de) | Hitzestabile plasmaproteinloesungen, verfahren zu ihrer herstellung und arzneipraeparate | |
DE69000713T2 (de) | Wismuthaltiges arzneipraeparat. | |
DE2504331A1 (de) | Heptaminol-5'-adenosinmonophosphat und dessen therapeutische verwendung | |
DE2652961A1 (de) | Propionsaeurederivate, verfahren zu ihrer herstellung und diese enthaltende arzneimittel | |
DE2623486C2 (de) | 3.5.5-Trimethylhexanoyl-ferrocen, Verfahren zu seiner Herstellung und pharmazeutische Präparate | |
DE3440621A1 (de) | Pharmazeutische zusammensetzung zur bekaempfung von vireninfektionen und deren verwendung | |
DE1802641A1 (de) | Antivirale Arzneimittel | |
DE3212909C2 (en:Method) | ||
DE3016359A1 (de) | Zahn- bzw. mundwasserloesung zur bildung von schutzfilem und hierfuer geeignetes verfahren | |
DE3780702T2 (de) | Verwendung von etodolac zur senkung des blutgehalts an harnsaeure. | |
DE3048154C2 (en:Method) | ||
DE1967088C3 (de) | N3-Disubstituierte Cysteine | |
DE951228C (de) | Verfahren zur Stabilisierung eines adrenocorticotropen Praeparates | |
DE2635293A1 (de) | Salzgemisch, insbesondere leicht assimilierbares arzneimittelgemisch mit erhoehter loeslichkeit, enthaltend kalziumsalze und/oder magnesiumsalze | |
DE3225491A1 (de) | Pharmazeutische zusammensetzung, ihre herstellung und verwendung | |
DE2614137C2 (de) | Benzo[b]thien(2)-ylaminoäthylketone, Verfahren zu ihrer Herstellung, sowie diese enthaltende Arzneimittel | |
DE1767994C2 (de) | Arzneimittel mit antacidem und absorptivem Wirkstoff | |
DE68905392T2 (de) | Penizillinpraeparat zur rektalen verabreichung. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8110 | Request for examination paragraph 44 | ||
8128 | New person/name/address of the agent |
Representative=s name: ZUMSTEIN SEN., F., DR. ASSMANN, E., DIPL.-CHEM. DR |
|
D2 | Grant after examination | ||
8364 | No opposition during term of opposition | ||
8339 | Ceased/non-payment of the annual fee |